Participating Companies

Ph3 ready hor­mone ther­a­py com­pany with an in­jectable, long-act­ing GnRH an­ta­g­on­ist for pros­tate can­cer and be­nign pro­stat­ic hy­per­pla­sia. An in­jectable en­ables ex­tend­ed drug ac­tiv­i­ty, which is im­por­tant for in­di­ca­tions with ac­tive oral an­ta­g­on­ists in late-stage de­vel­op­ment and al­so ap­proved agent(s). The safe­ty pro­file looks good with over 415 sub­jects dosed over 805 times. [more in­for­ma­tion]
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
AsclepiX Therapeutics
AX­T107 de­mon­s­trat­ed ef­fi­ca­cy and dura­bil­i­ty in rab­bit and mouse mod­els that is su­pe­ri­or to stan­dard of care Eye­lea. [more in­for­ma­tion]
BlinkBio, Inc.
They have in­no­vat­ed a plat­form based on Tun­able Drug Con­ju­gate (TDCs) ther­a­pies used to di­rect­ly tar­get the de­liv­ery of toxins to tu­mors. The lead ther­a­peu­tic pro­gram tar­gets Fo­late Re­cep­tor al­pha and has been vali­dat­ed in the clin­ic by ADCs, pro­vid­ing a de-risked bench­mark for plat­form vali­da­tion and can­di­date de­vel­op­ment. [more in­for­ma­tion]
Caribou Biosciences
Our sin­gu­lar fo­cus is on the ad­vance­ment of new ap­pli­ca­tions for CRIS­PR-Cas gene edit­ing that will help bring the tre­men­dous promise this tech­nol­o­gy holds for pa­tients and con­sumers to re­al­i­ty. [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1 pro­phy­lac­tic mR­NA ra­bies vax Oct 2018. Pro­phy­lac­tic in­fluen­za vax ini­ti­a­tion Ph 1 2020, OTC de­fi­cien­cy Ph 1 ini­ti­a­tion H219. In­ter­im da­ta /all trials: 2019. [more in­for­ma­tion]
Elstar Therapeutics, Inc.
El­s­tar Ther­a­peu­tics is ful­filling the promise of pre­ci­sion can­cer im­munother­a­py through a pow­er­ful new ap­proach to gen­er­at­ing anti­body-based, mul­ti-func­tio­n­al ther­a­peu­tics. El­s­tar’s Uni­ver­sal Tar­get­ed Im­munother­a­py (Uni­TI™) plat­form is po­si­tioned to over­come bar­ri­ers that are lim­it­ing the full po­ten­tial of other promis­ing im­munother­a­peu­tic ap­proach­es. [more in­for­ma­tion]
Goldfinch Bio
Just as the goldfinch has long been a sym­bol of heal­ing and re­ne­w­al and was a promi­nent fig­ure of the Re­nais­sance, Goldfinch Bio is lead­ing a new age of ther­a­peu­tic dis­cov­ery to trans­form the treat­ment paradigm for pa­tients with kid­ney dis­eas­es. [more in­for­ma­tion]
Grace Therapeutics
: self-fund­ed - 2 Ph 3 pro­grams in subarach­noid he­m­or­rhage (NDA fil­ing in 2019) and ataxia te­langiec­s­ta­sia, 1 Ph 2/3 in pos­ther­pet­ic neu­ral­gia (PHN) [all ap­proved or­phan desig­na­tion]; 2 add’l pro­grams (trigem­i­nal neu­ral­gia & aor­tic aneurysm). [more in­for­ma­tion]
Intensity Therapeutics
Sub­si­diary of Por­tage Biotech (seed in­ves­tor in Bio­haven). Raised $10m Se­ries A in June 2016 (In­ves­tors: Fast­For­ward In­no­va­tions, Bat­ter­son VC, VCap­i­tal, De­clan Doo­gan, Jim Mel­lon). Ini­ti­at­ed FIH trial to study ef­fects in solid tu­mors; trial aims to en­roll 60 pa­tients w dif­fer­ent types of ad­vanced solid tu­mor ma­lig­nan­cies in a mul­ti­cy­cle dos­ing reg­i­men [more in­for­ma­tion]
iOx Therapeutics
Sub­si­diary of Por­tage Biotech (seed in­ves­tor in Bio­haven). Launched by Lud­wig Can­cer Re­search & Uni­ver­si­ty of Ox­ford. De­vel­op­ing mul­ti­ple syn­thet­ic lipid com­pounds dis­cov­ered by re­search team led by Pro­fes­sor Vin­cen­zo Cerun­do­lo; Launch­ing first clin­i­cal trial in part­n­er­ship with UK Medicines and Health Prod­ucts Reg­u­la­to­ry Agen­cy & head­ed by Pro­fes­sor Mark Mid­dle­ton (Ox­ford) [more in­for­ma­tion]
NexImmune, Inc.
Anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Mul­ti­ple IND fil­ings exp H1'19. [more in­for­ma­tion]
Oyster Point Pharma, Inc.
The com­pany’s ini­tial fo­cus is to de­vel­op in­no­va­tive ther­a­peu­tics to treat the signs and symp­toms of Dry Eye Dis­ease (DED) by sti­m­u­lat­ing the Trigem­i­nal Parasym­pa­thet­ic Path­way to ac­ti­vate the glands re­spon­si­ble for tear film pro­duc­tion. [more in­for­ma­tion]
Phar­varis is fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. POC was de­mon­s­trat­ed in a mon­key mod­el and it’s ap­pli­ca­ble to all pa­tients in HAE. [more in­for­ma­tion]
PsiOxus Therapeutics
The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune cells in­to at­tack­ing tar­get­ed can­cer cells. Up­com­ing Mile­s­tones: - 2 pro­grams in clin­ic with read­outs in 2019 (ovarian can­cer in comb w Pa­cl­i­tax­el, car­ci­no­mas in comb w nivolumab) - 2 INDs in 2018 (NG-348 and NG-350A) - 2 INDs in 2019 (NG-641 and NG-347) [more in­for­ma­tion]
Quentis Therapeutics
Lead pro­gram is a first-in-class IRE1&al­pha; in­hibi­tor de­signed to boost an­ti-tu­mor im­mu­ni­ty in can­cer. Quen­tis is pur­su­ing ther­a­pies to ad­dress mul­ti­ple ER stress path­way tar­gets in the tu­mor mi­cro-en­vi­ron­ment, as well as in other dis­eas­es where ER stress plays an im­por­tant role. Quen­tis launched in Fe­bruary 2018 with a $48 mil­lion Se­ries A fi­nanc­ing. [more in­for­ma­tion]
Rapt Therapeutics
RAPT Ther­a­peu­tics is a clin­i­cal stage im­munol­o­gy-based bio­phar­ma­ceu­ti­cal com­pany fo­cused on dis­cov­er­ing, de­vel­op­ing and com­mer­cial­iz­ing oral small molecule ther­a­pies for pa­tients with sig­ni­f­i­cant un­met needs in on­col­o­gy and in­flam­ma­to­ry dis­eas­es. [more in­for­ma­tion]
Tango Therapeutics
Tan­go Ther­a­peu­tics is a biotech­nol­o­gy com­pany ded­i­cat­ed to dis­cov­er­ing nov­el drug tar­gets and de­liv­er­ing the next gen­er­a­tion of tar­get­ed ther­a­pies to peo­ple with can­cer. [more in­for­ma­tion]
TRIGR Therapeutics
Bis­pe­cif­ic Abs: du­al an­gio­ge­n­e­sis in­hibi­tor (TR009) and 3 im­muno­mo­d­u­la­to­ry du­al check­point & T cell en­gag­ing Bs­Abs. AS­CO TR009 P1a re­sults. In­ter­im P1a dose es­ca­la­tion: clin ben­e­fit of 66%, one PR (7.5mg) no DLTs in solid tu­mors [more in­for­ma­tion]
Viela Bio
Lead pro­gram, Ine­bi­l­izumab, is a CD19 mAb which met the pri­mary end­point in the Ph 2b piv­o­tal study for the treat­ment of Neu­romyeli­tis Op­ti­ca. Pri­mary anal­y­sis de­mon­s­trat­ed a 77% re­duc­tion in the risk of de­vel­op­ing NMOSD at­tack in pa­tients treat­ed with ine­bi­l­izumab monother­a­py com­pared to place­bo. [more in­for­ma­tion]